3759 — Pharmaron Beijing Co Share Price
Last trade - 00:00- HK$38.14bn
- HK$43.41bn
- CNY12.28bn
- 78
- 27
- 44
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.03 | ||
| PEG Ratio (f) | 0.77 | ||
| EPS Growth (f) | 24.09% | ||
| Dividend Yield (f) | 1.33% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.32 | ||
| Price to Tang. Book | 3.14 | ||
| Price to Free Cashflow | 42.32 | ||
| Price to Sales | 2.5 | ||
| EV to EBITDA | 19.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.83% | ||
| Return on Equity | 10.8% | ||
| Operating Margin | 13.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 5,133.6 | 7,443.77 | 10,266.29 | 11,538 | 12,275.77 | 14,035.89 | 16,141.26 | 26.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +79.29 | +38.29 | -27.5 | +32.87 | +20.72 | -6.61 | +24.09 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmaron Beijing Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The Company operates through five segments. The Laboratory Services segment includes laboratory chemistry and bioscience services, covering small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates, and cell and gene therapy products. The Chemical and Formulation Process Development and Manufacturing Services segment includes active pharmaceutical ingredient process development and manufacturing, as well as preformulation and formulation development. The Clinical Research Services segment includes international and domestic clinical research services. The Large Molecule and Cell and Gene Therapy Services segment includes large molecule drug discovery, development, and manufacturing services, as well as cell and gene therapy laboratory and gene therapy drug development and manufacturing services. The Company also operates through the others segment.
Directors
- Boliang Lou CHM (57)
- Shing Chung Li CFO (42)
- Xiaoqiang Lou COO (52)
- Bei Zheng EVP (53)
- Hua Yang CSO (58)
- Pingjin Chen NED (51)
- Baifeng Hu NED (39)
- Jiaqing Li NED (47)
- Hongbin Zhou NED (48)
- Guoqin Chen NID (49)
- Lixin Dai NID (96)
- Kwan Hung Tsang NID (56)
- Jian Yu NID (47)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- July 1st, 2004
- Public Since
- January 28th, 2019
- No. of Shareholders
- 77,484
- No. of Employees
- 21,370
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,830,020,328
- Address
- No. 6 Taihe Road, Beijing Economic and T, BEIJING, 100176
- Web
- https://www.pharmaron.cn/
- Phone
- +86 1057330087
- Contact
- Shing Chung Li
- Auditors
- Ernst & Young Hua Ming LLP
Upcoming Events for 3759
Similar to 3759
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:38 UTC, shares in Pharmaron Beijing Co are trading at HK$20.84. This share price information is delayed by 15 minutes.
Shares in Pharmaron Beijing Co last closed at HK$20.84 and the price had moved by +39.49% over the past 365 days. In terms of relative price strength the Pharmaron Beijing Co share price has underperformed the FTSE Developed Asia Pacific Index by -8.33% over the past year.
The overall consensus recommendation for Pharmaron Beijing Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Pharmaron Beijing Co dividend yield is 1.08% based on the trailing twelve month period.
Last year, Pharmaron Beijing Co paid a total dividend of CNY0.20, and it currently has a trailing dividend yield of 1.08%. We do not have any data on when Pharmaron Beijing Co is to next pay dividends.
We do not have data on when Pharmaron Beijing Co is to next pay dividends. The historic dividend yield on Pharmaron Beijing Co shares is currently 1.08%.
To buy shares in Pharmaron Beijing Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$20.84, shares in Pharmaron Beijing Co had a market capitalisation of HK$38.14bn.
Here are the trading details for Pharmaron Beijing Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3759
Based on an overall assessment of its quality, value and momentum Pharmaron Beijing Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pharmaron Beijing Co is HK$28.87. That is 38.52% above the last closing price of HK$20.84.
Analysts covering Pharmaron Beijing Co currently have a consensus Earnings Per Share (EPS) forecast of CNY0.99 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmaron Beijing Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.91%.
As of the last closing price of HK$20.84, shares in Pharmaron Beijing Co were trading +0.89% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharmaron Beijing Co PE ratio based on its reported earnings over the past 12 months is 15.03. The shares last closed at HK$20.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pharmaron Beijing Co's management team is headed by:
- Boliang Lou - CHM
- Shing Chung Li - CFO
- Xiaoqiang Lou - COO
- Bei Zheng - EVP
- Hua Yang - CSO
- Pingjin Chen - NED
- Baifeng Hu - NED
- Jiaqing Li - NED
- Hongbin Zhou - NED
- Guoqin Chen - NID
- Lixin Dai - NID
- Kwan Hung Tsang - NID
- Jian Yu - NID